

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 75160

Title: Peroxisome Proliferator-Activated Receptor-Gamma as a therapeutic target for

hepatocellular carcinoma: Experimental and Clinical scenario

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05127202 Position: Peer Reviewer Academic degree: PhD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: India

Manuscript submission date: 2022-01-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-18 06:57

Reviewer performed review: 2022-01-18 07:06

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No



https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This review discussed the regulatory role of PPAR γ in HCC pathogenesis and experimental and clinical scenario PPAR γ agonist in HCC treatment. The content was novel and valuable. The article was well written and there were no obvious mistakes in the sentences.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 75160

Title: Peroxisome Proliferator-Activated Receptor-Gamma as a therapeutic target for

hepatocellular carcinoma: Experimental and Clinical scenario

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03766000 Position: Editorial Board Academic degree: MD, PhD

Professional title: Assistant Professor, Research Assistant Professor

Reviewer's Country/Territory: China

Author's Country/Territory: India

Manuscript submission date: 2022-01-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-21 01:13

Reviewer performed review: 2022-02-23 08:44

Review time: 2 Days and 7 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No



Baishideng Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In this review, Swati Katoch et al summarized the recent progress in the role of PPARy as a therapeutic target for hepatocellular carcinoma, focusing on the various PPARy agonists. It is well-written with beautiful figures. I think it is very useful the specialists in this area.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 75160

Title: Peroxisome Proliferator-Activated Receptor-Gamma as a therapeutic target for

hepatocellular carcinoma: Experimental and Clinical scenario

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03478911 Position: Associate Editor Academic degree: PhD

Professional title: Chief Technician, Executive Vice President, Research Assistant

Professor

Reviewer's Country/Territory: South Korea

Author's Country/Territory: India

Manuscript submission date: 2022-01-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-19 06:56

Reviewer performed review: 2022-02-28 00:21

Review time: 8 Days and 17 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection



Re-review	[]Yes [Y]No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This review provides comprehensive information on therapeutic effect through known small molecules derived from synthetic or natural that can exert an agonism on PPARs. However, in the course of describing the nonclinical and/or clinical efficacy of all the presented agents, only their merits are highlighted. The therapeutic limitations of the agents(eg. druggability, resistance, adverse effect, and so on) must be indicated in each paragraph.